Literature DB >> 16284356

Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales.

P Geborek, E Nitelius, S Noltorp, H Petri, L Jacobsson, L Larsson, T Saxne, I Leden.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16284356      PMCID： PMC1755306          DOI： 10.1136/ard.2005.036715

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

1.  Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy.

Authors:  Subash C Gupta; David Hevia; Sridevi Patchva; Byoungduck Park; Wonil Koh; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2012-01-16       Impact factor: 8.401

2.  Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.

Authors:  Lennart T H Jacobsson; Carl Turesson; Jan-Ake Nilsson; Ingemar F Petersson; Elisabet Lindqvist; Tore Saxne; Pierre Geborek
Journal:  Ann Rheum Dis       Date:  2006-12-11       Impact factor: 19.103

3.  The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines.

Authors:  Christine Y Lu; Kenneth M Williams; Richard O Day
Journal:  Aust New Zealand Health Policy       Date:  2007-03-01

4.  Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.

Authors:  Lars Erik Kristensen; Tore Saxne; Jan-Ake Nilsson; Pierre Geborek
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

5.  EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.

Authors:  Tanja Schjødt Jørgensen; Carl Turesson; Meliha Kapetanovic; Martin Englund; Aleksandra Turkiewicz; Robin Christensen; Henning Bliddal; Pierre Geborek; Lars Erik Kristensen
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

6.  Patients with ankylosing spondylitis have increased sick leave--a registry-based case-control study over 7 yrs.

Authors:  Britta Strömbeck; Lennart T H Jacobsson; Ann Bremander; Martin Englund; Anders Heide; Aleksandra Turkiewicz; Ingemar F Petersson
Journal:  Rheumatology (Oxford)       Date:  2009-01-22       Impact factor: 7.580

7.  Early menopause and severity of rheumatoid arthritis in women older than 45 years.

Authors:  Mitra Pikwer; Jan-Åke Nilsson; Ulf Bergström; Lennart T H Jacobsson; Carl Turesson
Journal:  Arthritis Res Ther       Date:  2012-08-17       Impact factor: 5.156

8.  Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.

Authors:  Jon Thorkell Einarsson; Max Evert; Pierre Geborek; Tore Saxne; Maria Lundgren; Meliha C Kapetanovic
Journal:  Clin Rheumatol       Date:  2017-10-04       Impact factor: 2.980

9.  Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis.

Authors:  Emil Rydell; Kristina Forslind; Jan-Åke Nilsson; Lennart T H Jacobsson; Carl Turesson
Journal:  Arthritis Res Ther       Date:  2018-05-02       Impact factor: 5.156

10.  Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis.

Authors:  Lisa Theander; Minna Willim; Jan Åke Nilsson; Magnus Karlsson; Kristina E Åkesson; Lennart T H Jacobsson; Carl Turesson
Journal:  RMD Open       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.